SV2A and Parkinson disease: Disease-specific changes in SV2A density, i.e., synaptic loss, has now been demonstrated in rodent models of neurodegeneration with intracranial injections of neurotoxic agents or with protein inoculation models of PD (Thomsen et al., 2021a,b).